Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ArcelorMittal SA (MT) vs Viatris Inc (VTRS) Price & Performance

ArcelorMittal SATrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

ArcelorMittal SA vs Viatris Inc — how do they compare? ArcelorMittal SA trades at $73.73 (market cap $55.96B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: ArcelorMittal SA is far larger — about 3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.

MTVTRS
Market Cap
$55.96B$18.69B
Sector
Basic MaterialsHealth
52-Week High
$75.35$17.86
52-Week Low
$32.44$9.49
Enterprise Value
$65.53B$30.81B
Dividend Yield
0.81%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ArcelorMittal SA

ArcelorMittal (MT) trades at $73.29, up 0.1% with bullish technical signals from moving averages despite recent earnings miss. The company shows improving fundamentals with Q2 2026 revenue growth and strong cash flow generation of $4.8B from operations. Recent corporate developments include dividend payments and strategic partnerships with Microsoft, while analyst consensus remains positive with 50% buy ratings.

Outlook remains cautiously optimistic with European business recovery potential, though risks include cyclical steel demand volatility and elevated debt levels. The stock offers value with reasonable P/S (0.89) and P/B (1.01) ratios, but investors should monitor execution on second-half shipment guidance and margin pressures from input costs.

Viatris Inc

Viatris (VTRS) trades at $16.43, up 0.86% with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, with revenues rising 5% year-over-year. However, fundamental challenges persist with negative net income margin (-2.79%) and elevated P/E ratio (236.2). Recent developments include FDA approval for Gwyn Lo contraceptive patch and strategic divestitures to sharpen focus.

While Viatris shows operational improvements with consistent cash flow generation, the stock faces headwinds from profitability challenges and high valuation multiples. The mixed analyst sentiment (30.77% buy rating) reflects uncertainty about the company's turnaround trajectory. Key risks include ongoing margin pressure and competitive threats in the generic pharmaceutical space.

Returns comparison

Trailing returns across standard periods

About ArcelorMittal SA

ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA

Read more on MT

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS